Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
QL1706 + lenvatinib is a combination therapy under investigation for the treatment of various cancers. QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies, functioning as a dual immune checkpoint inhibitor to enhance antitumor immune responses[1][2][3]. Lenvatinib is an oral small molecule receptor tyrosine kinase inhibitor that targets multiple kinases involved in tumor angiogenesis and proliferation, including VEGFR1–3, FGFR1–4, PDGFRα, KIT, and RET[6][8]. The combination aims to leverage both immune modulation (via checkpoint inhibition) and antiangiogenic/antiproliferative effects (via kinase inhibition). Clinical trials are ongoing for several solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, hepatocellular carcinoma (HCC), among others[2][3][7].
- Other names
- lenvatinib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on QL1706 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + lenvatinib.